

# List of Tables

---

## List of Tables

<b>Chapter 1</b>	<b>Page No.</b>
Table 1.1: Chemotherapeutic agents with their physicochemical properties for treatment of gliomas	3
Table 1.2: Targeted toxins used against brain tumors	4
Table 1.3: Various nano-formulations for treatment of brain tumor which are under clinical trials	8
<b>Chapter 2</b>	<b>Page No.</b>
Table 2.1: List of metal nanoparticles in the market and in clinical trials	35
Table 2.2: Methods for synthesis of Metal/Alloy nanoparticles	36
Table 2.3: Review of Research Conducted on Lenalidomide	41
Table 2.4: Applications of magnetic nanoparticles in cancer treatment	
<b>Chapter 3</b>	<b>Page No.</b>
Table 3.1: Calibration curve for LND in PBS (pH 7.4) by UV Visible spectrophotometer.	95
Table 3.2: Calibration curve for LND in CPB (pH 5.5) by UV visible spectrophotometer	96
Table 3.3: Accuracy of analytical method in PBS 7.4 and CPB 5.5	97
Table 3.4: Precision of analytical method in PBS 7.4	98
Table 3.5: Precision of analytical method in CPB 5.5	98
Table 3.6. Calibration curve of LND in Methanol by UV visible spectrophotometer	99
Table 3.7. Calibration curve of Iron in distilled water by UV visible spectrophotometer	100
Table 3.8: Calibration curve of LND in plasma by spectrofluorimetry	102
Table 3.9: Interference study data of LND,HA and CMHA	104
<b>Chapter 6</b>	<b>Page No.</b>
Table 6.1: RPN of selected factors for selection of critical variables	148

## List of Tables

---

Table 6.2: Working range of selected factors for synthesis of FePt nanoparticles	152
Table 6.3: Experimental runs obtained using BBD	153
Table 6.4: Predicted and obtained value for desirability plot for synthesized FePt nanoparticles	159
Table 6.5: Effect of variation in CPP on particle size and atomic composition of FePt nanoparticles	162
Table 6.6: Final operating range of factors for synthesis of FePt nanoparticles	162
Table 6.7: Optimization of Phase transfer condition and process for FePt nanoparticles	164
Table 6.8: Characterization of FePt, FePt-NH <sub>2</sub> and NH <sub>2</sub> -FePt-COOH nanoparticles	167
Table 6.9: Elemental composition of FePt, FePt-NH <sub>2</sub> and COOH-FePt-NH <sub>2</sub> nanoparticles	170
Table 6.10: Stability study of SH-FePt and FePt-COOH (synthesized using PAA)	171
Table 6.11: Optimization data for synthesis of Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles	172
Table 6.12: Particle size and zeta potential of surface modified nanoparticles	173
Table 6.13: SAR of FePt and Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles in PBS and 5% agarose gel	182
Table 6.14: Heating power of FePt and Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles suspension	185
Table 6.15: Heating power of FePt and Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles in U87MG cells.	185
Table 6.16: FTIR spectrum data for HA & CMHA	187
Table 6.17: Optimization of Conjugation Efficiency of CMHA-Lenalidomide Conjugates	189
Table 6.18: FT-IR spectra of CMHA-drug conjugate	189
Table 6.19: Calculation and Optimization of Drug Loading	194
Table 6.20: Mucus penetration ability of SPANs	195
Table 6.21: Interaction of surface modified Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles with Mucin.	196
Table 6.22: Interaction of surface modified Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles with ECM.	197
Table 6.23: Interaction of surface modified Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles with Plasma	198
Table 6.24: Results of % Haemolysis by surface modified Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles	199
Table 6.25: Stability of surface modified Fe <sub>2</sub> O <sub>3</sub> @FePt nanoparticles in DMEM	200
Table 6.26: Nanoparticles and protein corona	200

## List of Tables

---

<b>Chapter 8</b>	<b>Page No.</b>
Table 8.1: Groups of animals for pharmacokinetic study	237
Table 8.2: Concentration of LND in rat plasma after intranasal administration of drug suspension, SPANs and M-SPANs	246
Table 8.3: Concentration of LND in rat plasma after intravenous administration of drug suspension, SPANs and M-SPANs	247
Table 8.4: Comparative pharmacokinetic parameters of LND delivered in suspension, SPANs and M-SPANs via intranasal route	247
Table 8.5: Comparative pharmacokinetic parameters of LND delivered in suspension, SPANs and M-SPANs via intravenous route	247
Table 8.6: Pharmacokinetics parameters of M-SPANs after intranasal and intravenous administration	249
Table 8.7: Biodistribution pattern of 177M-SPANs administered via intranasal route	253
Table 8.8: Effect of M-SPANs on liver function	256
Table 8.9 Effect of M-SPANs on glutathione and lipid peroxidation levels in mouse liver	256
Table 8.10: Assessment of interaction between M-SPANs and bio-molecules (plasma, mucin and ECM)	257